PI3K-AKT Signaling Pathway
The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of stimuli and controls fundamental cellular processes such as apoptosis, metabolism, proliferation, protein synthesis, growth, and survival. Dysregulation of this pathway is implicated in a number of disease states including cardiovascular and neurological disease, diabetes, and particularly cancer. This has led to the development of a number of small molecule inhibitors of both PI3K and Akt for use in therapeutic treatment of some of these diseases.


Related Products
Featured Publications
Qiao L, Hu S, Liu S, et al. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. J Clin Invest. 2019;129(6):2237-2250. Published 2019 Apr 29. doi:10.1172/JCI123135
Species: Human
Sample type: Cell Lysate (iCM, H9C2, HCF, HUVEC cells )
View Publication
Yang Y, Wang J, Guo S, et al. Non-lethal sonodynamic therapy facilitates the M1-to-M2 transition in advanced atherosclerotic plaques via activating the ROS-AMPK-mTORC1-autophagy pathway. Redox Biol. 2020;32:101501. doi:10.1016/j.redox.2020.101501
Species: Mouse
Sample type: Conditioned Media
View Publication
Wang N., Rayes R., Elahi S., et al. The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis. Mol Cancer Ther. 2015 Apr;14(4):982-93. doi: 10.1158/1535-7163.MCT-14-0751.
Species: Mouse
Sample type: Cell Lysate (Metastatic colon carcinoma cell lines MC-38 and Lewis lung carcinoma H-59 cells.)
View Publication
Luszczak, S., Simpson, B.S., Stopka-Farooqui, U. et al. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Sci Rep 10, 14380 (2020). https://doi.org/10.1038/s41598-020-71263-9
Species: Human, Mouse
Sample type: Conditioned media (cell culture media)
View Publication
Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Sci Rep. 2020 Sep 1;10(1):14380. doi: 10.1038/s41598-020-71263-9. Erratum in: Sci Rep. 2020 Nov 11;10(1):19870. PMID: 32873828; PMCID: PMC7463239.
Species: Human
Sample type: Conditioned Media
View Publication